NL-OMON54744招募中不适用
A Phase 1, Open-Label, Dose-Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MCLA-145 in Participants With Advanced or Metastatic Malignancies - MCLA-145-CL01 study / M19MC
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Merus N.V.
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •- Participants with melanoma, head and neck squamous cell carcinoma (HNSCC),
- •urothelial carcinoma, NSCLC, MSI-H/dMMR tumors, or triple negative breast
- •cancer (TNBC)
- •- Tumor should histologically or cytologically confirmed
- •See protocol for more detailed criteria.
排除标准
- •- The following B-cell neoplasms: Burkitt lymphoma, lymphoblastic
- •leukemia/lymphoma, lymphoplasmacytic lymphoma, chronic lymphocytic leukemia
- •- Prior therapy containing a 4-1BB agonist or prior therapy with CAR T-cell
- •See protocol for more detailed criteria.
研究者
相似试验
招募中
不适用
A Phase 1 Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules given alone or in combination with Paclitaxel in patients with Advanced Gastric CancerNeoplasmsKCT0006519Samsung Medical Center18
进行中（未招募）
1 期
Gene Therapy in patients with Mucopolysaccharidosis diseaseThe clinical trial will be conducted on patients withMucopolysaccharidosis Type VI. MPS VI is characterized by growthretardation, corneal clouding, cardiac valve disease, organomegaly, skeletal dysplasia, without central nervous system involvementEUCTR2016-002328-10-NLFONDAZIONE TELETHO10
尚未招募
不适用
A Phase I/II Open Label, Dose Escalation, Safety Study in Subjects with Mucopolysaccharidosis type VI (MPS VI) Using Adeno-Associated Viral Vector 8 to Deliver the human ARSB gene to Liver.NL-OMON47624Fondazione Telethon4
进行中（未招募）
1 期
Gene Therapy in patients with Mucopolysaccharidosis diseaseEUCTR2016-002328-10-ITFONDAZIONE TELETHO10
进行中（未招募）
1 期
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)Advanced MalignanciesMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2016-002831-14-DKIncyte Corporation325